Compounds > moxifloxacin

Page last updated: 2024-09-04

moxifloxacin and bc-3781

moxifloxacin has been researched along with bc-3781 in 5 studies

Compound Research Comparison

Studies (moxifloxacin)	Trials (moxifloxacin)	Recent Studies (post-2010) (moxifloxacin)	Studies (bc-3781)	Trials (bc-3781)	Recent Studies (post-2010) (bc-3781)
3,157	552	1,690	41	10	41

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (20.00)	24.3611
2020's	4 (80.00)	2.80

Authors

Authors	Studies
Das, A; File, TM; Gasink, LB; Gelone, SP; Goldberg, L; Paukner, S; Saviski, J; Seltzer, E; Sweeney, C; Talbot, GH; Wicha, WW	1
Donato, A; Powell, D	1
Lai, CC; Tang, HJ; Wang, JH	1
Alexander, E; Das, AF; File, TM; Goldberg, L; Moran, GJ; Paukner, S; Sandrock, C	1
Alexander, E; Das, AF; File, TM; Gelone, SP; Goldberg, L; Heinrich, S; Moran, GJ; Patel, P; Paukner, S; Sandrock, C; Schranz, J; Vidal, JE; Waites, KB	1

Trials

4 trial(s) available for moxifloxacin and bc-3781

Article	Year
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 11-13, Volume: 69, Issue:11 Topics: Administration, Intravenous; Adult; Aged; Anti-Bacterial Agents; Diterpenes; Double-Blind Method; Female; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pleuromutilins; Pneumonia, Bacterial; Polycyclic Compounds; Randomized Controlled Trials as Topic; Thioglycolates	2019
Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia. Medicine, 2020, Jul-17, Volume: 99, Issue:29 Topics: Aged; Anti-Bacterial Agents; Community-Acquired Infections; Diterpenes; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Polycyclic Compounds; Streptococcus pneumoniae; Taiwan; Thioglycolates; Treatment Outcome	2020
Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities. BMC pulmonary medicine, 2021, May-08, Volume: 21, Issue:1 Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Comorbidity; Diterpenes; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Polycyclic Compounds; Thioglycolates; United States; Young Adult	2021
Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin. Journal of global antimicrobial resistance, 2022, Volume: 29 Topics: Adult; Bacteria; Coinfection; Community-Acquired Infections; Diterpenes; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pneumonia, Bacterial; Polycyclic Compounds; Thioglycolates	2022

Other Studies

1 other study(ies) available for moxifloxacin and bc-3781

Article	Year
In community-acquired bacterial pneumonia, lefamulin was noninferior to moxifloxacin at 96 h after the first dose. Annals of internal medicine, 2020, 02-18, Volume: 172, Issue:4 Topics: Adult; Community-Acquired Infections; Diterpenes; Humans; Moxifloxacin; Pneumonia, Bacterial; Polycyclic Compounds; Thioglycolates	2020